Administrative Core

摘要 将先进的工程工具和方法整合到免疫疗法开发项目中， 提高临床前治疗开发管道效率的潜力。建立一个强大的免疫- 工程翻译加速器（ITA）是PPG的一个战略目标，与科学翻译加速器并列。 项目的目标。行政核心将为此提供全面领导和行政支助。 PPG在推进PPG的科学目标以及更广泛的目标，建立一个转型的ITA。 核心将促进每周会议和半年期讲习班，促进项目编制补助金项目的整合， 支持从这个PPG中出现的翻译活动，并建立一个合作和创新的癌症 明尼苏达大学的免疫工程社区。行政核心将由首席执行官领导 大卫奥德（生物医学工程师）、大卫马索普斯特（癌症免疫学家）和大卫Largaespada（基因组 工程师），并得到Paolo Provenzano（生物医学工程师）、Ingunn Stromness（癌症 Branden Moriarity（基因组工程师）。行政核心的工作将得到促进 项目经理博·康奈利 为促进实现本方案编制小组的广泛目标，行政核心将实现以下具体目标： 目标1 -提供强有力和一致的领导和管理，最大限度地发挥PPG的影响。 目标2 -评估和促进科学进步。 目标3 -建立一个协作，支持和创新的癌症免疫生物工程社区。 目标4 -通过创建免疫工程翻译支持和加速临床翻译 加速器（ITA）。

Abstract Integrating advanced engineering tools and approaches into immunotherapy development projects holds the potential to improve the efficiency of the pre-clinical therapy development pipeline. Developing a robust Immuno- engineering Translation Accelerator (ITA) is a strategic goal for this PPG that stands alongside the scientific goals of the Projects. The Administrative Core will provide overall leadership and administrative support to this PPG in furtherance of the PPG’s scientific goals as well as the broader goal to establish a transformational ITA. The Core will facilitate weekly meetings and semi-annual workshops, promote integration of the PPG projects, support translational activities that emerge from this PPG, and build a collaborative and innovative cancer immuno-engineering community at the University of Minnesota. The Administrative Core will be led by MPIs David Odde (Biomedical Engineer), David Masopust (Cancer Immunologist), and David Largaespada (Genome Engineer) with support from Paolo Provenzano (Biomedical Engineer), Ingunn Stromness (Cancer Immunologist), and Branden Moriarity (Genome Engineer). The work of the Administrative Core will be facilitated by Program Manager Bo Connelly. To facilitate the broad goals of this PPG, the administrative core will implement the following specific aims: Aim 1 – Provide strong and consistent leadership and management that maximizes PPG impact. Aim 2 – Evaluate and facilitate scientific progress. Aim 3 – Build a collaborative, supportive, and innovative cancer immune bioengineering community. Aim 4 – Support and accelerate clinical translational through the creation of an Immuno-Engineering Translation Accelerator (ITA).